A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane

Type of Cancer
Breast Oncology

Sponsor
Odonate Therapeutics

Protocol Number
ODO-TE-B301

To Learn More Call
(201)-510-0950